All In Biotech

Drug Trial Radar · NCT01918397

Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB

Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB

Last checked: Nov 19, 2026Latest source record: May 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

111

Actual

Start

Jan 2015

Primary completion

Mar 29, 2022

Study completion Mar 29, 2022

Sponsor

Lead sponsor
Boston UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); Centers for Disease Control and Prevention; Macleods Pharmaceuticals Ltd
First posted
Aug 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-drug-resistant tuberculosis (MDR-TB) affects nearly 600,000 persons each year around the world. This type of tuberculosis is very difficult to treat, and many patients die from it. Drugs of the fluoroquinolone class are very important for treating MDR-TB, but the best dose of one of the most effective fluoroquinolones, levofloxacin, is not known. This application proposes a study to determine the best dose of levofloxacin to use in treating MDR-TB. 120 patients will receive their usual treatment, plus levofloxacin at one of four doses. The study will be performed in Peru and in South Africa, where MDR-TB is common.

Conditions

  • Tuberculosis, Multidrug-Resistant

Interventions

  • LevofloxacinDrug

    Levofloxacin is a quinolone antibiotic used to treat lung, sinus, skin, and urinary tract infections caused by bacteria. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido\[1,2,3-de\]-1,4benzoxazine-6-carboxylic acid hemihydrate.

  • Optimized background regimen (OBR)Drug

    For this study "OBR" will mean optimized background regimen, not including a quinolone. OBR will be selected at the discretion of the study investigator to conform with standards of care and local site guidelines. In general, the OBR regimen should include at least 3 drugs (other than levofloxacin) to which the patient's isolate is not expected to be resistant, with one of these being an injectable agent, at the usual recommended doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Sputum Culture ConversionTime frame: 28 weeks
  2. Number of Grade 3,4, and 5 AEsTime frame: 28 weeks

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Partners in Health

    Lima, Peru

  • University of Cayetana Heredia

    Lima, Peru

  • Stellenbosch University

    Cape Town, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.